May 17, 2018 / 11:13 AM / 2 months ago

BRIEF-Syndax Announces Updated Results From Phase 2 Encore 601 Trial Of Entinostat In Combination With Keytruda®

May 17 (Reuters) - Syndax Pharmaceuticals Inc:

* SYNDAX ANNOUNCES UPDATED RESULTS FROM PHASE 2 ENCORE 601 TRIAL OF ENTINOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)

* SYNDAX PHARMACEUTICALS INC - POTENTIAL REGISTRATION PATHWAY IDENTIFIED IN NSCLC; NEXT TRIAL ANTICIPATED TO COMMENCE BY END OF 2018

* SYNDAX PHARMACEUTICALS INC - CONFIRMED OBJECTIVE RESPONSES WITH COMBINATION REGIMEN HAVE BEEN OBSERVED ACROSS ALL COHORTS IN PHASE 2 TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below